Clinical trials are research studies designed to discover new ways to treat different cancers, and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.
Thompson was the first to bring cancer clinical trials to East Tennessee more than 25 years ago. Today, Thompson’s clinical trials department is under the leadership of David Chism, MD and Susan Owenby, RN, CCRP, System Director of Clinical Research. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.
Thompson Cancer Survival Center offers clinical trials at the following Thompson Oncology Group locations:
- Blount
- Downtown Knoxville
- Lenoir City
- Oak Ridge
- West Knoxville
Bladder
| Protocol Number | NCT Number | Title | Principal Investigator |
|
A Phase II Open-Label, Study of IMMU-132 in Metastatic Urothelial Cancer |
David Chism, MD |
Breast
| Protocol Number | NCT Number | Title | Principal Investigator |
|
A Phase III, Randomized, Double-Blind, Placebo-Controlled clinical trial to evaluate the efficacy and safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at high risk of recurrence following preoperative therapy |
David Chism, MD |
||
|
|
A Phase III, Double-blind, Randomised Study to |
David Chism, MD |
|
|
A Phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of Giredestrant plus Everolimus compared with Exemestane plus Everolimus in patients with estrogen receptor-positive, her2- negative, locally advanced or metastatic breast cancer |
David Chism, MD |
||
| D9673R00025 (Destiny) DB-Respond
|
“A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+ and HER2-low unresectable and/or metastatic breast cancer” |
David Chism, MD |
Esophageal
| Protocol Number | NCT Number | Title | Principal Investigator |
|
|
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) |
David Chism, MD |
|
|
PHASE III RANDOMIZED TRIAL OF PROTON BEAM THERAPY (PBT) VERSUS INTENSITY MODULATED PHOTON RADIOTHERAPY (IMRT) FOR THE TREATMENT OF ESOPHAGEAL CANCER |
Grant Clark, MD |
Gastrointestinal
| Protocol Number | NCT Number | Title | Principal Investigator |
| NRG-GI005 | NCT04068103 |
Phase II/III Study of Circulating tumor DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
|
David Chism, MD |
| EA2176 | NCT04444921 |
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients |
David Chism, MD |
Genitourinary
| Protocol Number | NCT Number | Title | Principal Investigator |
| NRG-GU009 | NCT04513717 | Parallel Phase III Randomized Trials for High Risk Prostate Cancer evaluating De-Intensification for Lower Genomic risk and intensification of concurrent therapy for Higher Genomic risk with radiation (PREDICT-RT*) *Prostate RNA Expression/Decipher to Individualize Concurrent Therapy with Radiation | David Chism, MD |
| H-300-001 |
A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants with Metastatic Castration-Resistant Prostate Cancer |
David Chism, MD | |
| D910PC00001 (VOLGA) |
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA) |
David Chism, MD
|
Head and Neck
| Protocol Number | NCT Number | Title | Principal Investigator |
| EA3202 | NCT05063552 | A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers | David Chism, MD |
Kidney
| Protocol Number | NCT Number | Title | Principal Investigator |
| BO43936 (Triplet RCC) | NCT05805501 | A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations with Axitinib in patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | David Chism, MD |
| XL092-304 (STELLAR) | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | David Chism, MD |
Leukemia/Lymphoma
| Protocol Number | NCT Number | Title | Principal Investigator |
| AZA-MDS-006 (CONNECT) | NCT01688011 | The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | David Chism, MD |
| NDS-DLBCL-003 |
NCT04982471 |
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study |
David Chism, MD
|
| M22-132 | NCT05283720 |
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma |
David Chism, MD |
| C4971003 | A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | David Chism, MD |
Lung: Non-Small Cell
| Protocol Number | NCT Number | Title | Principal Investigator |
| BX43361 | NCT054191375 | Master screening study to determine biomarker status and potential trial eligibility for patients with malignant tumors | David Chism, MD |
| BO42777 | NCT05170204 | A phase i-iii, multicenter study evaluating the efficacy and safety of multiple therapies in cohorts of patients selected according to biomarker status, with locally advanced, unresectable, stage iii non-small cell lung cancer | David Chism, MD |
|
Phase II, Open-Label Safety and Efficacy Study of Telisotuzuumab Vedotin (ABBV-399) in Subjects with previously Treated c-Met+ NSCLC Non-Squamous |
David Chism, MD | ||
|
Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 (efineptakin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1-expressing, locally advanced or metastatic Non-Small Cell LunA multicenter, open-label, single-arg Cancer |
David Chism, MD | ||
| BO42592 (SKYSCRAPER-06)
|
A PHASE II/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER |
David Chism, MD | |
| 213410 |
A RANDOMIZED, OPEN-LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON PRIOR ANTI-PD-(L)1 THERAPY AND CHEMOTHERAPY (COSTAR LUNG) |
David Chism, MD
|
Melanoma
| Protocol Number | NCT Number | Title | Principal Investigator |
| EA6141 | NCT02339571 | Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | David Chism, MD |
Pancreatic
| Protocol Number | NCT Number | Title | Principal Investigator |
| EA2186 (GIANT) | NCT04233866 | A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT) | David Chism, MD |
Clinical Trial Studies – COMING SOON
<!–
| Protocol Number | NCT Number | Title | Principal Investigator |
| SGNDV-001 |
|
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer that Expresses HER2 (IHC 1+ and Greater) |
David Chism, MD |
| D910PC00001 (VOLGA) | NCT04960709 |
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer – (VOLGA) |
David Chism, MD |
| Protocol Number | NCT Number | Title | Principal Investigator |
| BO43936 (Skyscraper 10) | A Randomized Open Label Phase II Study of Immune Checkpoint Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | David Chism, MD |
–>
Genitourinary
| Protocol Number | NCT Number | Title | Principal Investigator |
| SGNDV-001 |
|
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer that Expresses HER2 (IHC 1+ and Greater) |
David Chism, MD |
| D910PC00001 (VOLGA) | NCT04960709 |
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer – (VOLGA) |
David Chism, MD |
Renal Cell Carcinoma
| Protocol Number | NCT Number | Title | Principal Investigator |
| BO43936 (Skyscraper 10) | A Randomized Open Label Phase II Study of Immune Checkpoint Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | David Chism, MD |
Patient Stories
-
This blog was written using content provided by Jessica Severt, RN, BSN, Clinical Research Nurse Coordinator, Thompson Cancer Survival Center Around 14% of new breast cancer diagnoses are categorized as HER2-positive which is generally associated with more aggressive cancer1. HER2-positive means an overexpression (too much) of the HER2 protein is found in the breast tumor […]
-
Created with content provided by Jessica Severt, RN, BSN, Clinical Research Nurse Coordinator at Thompson Cancer Survival Center Have you ever wondered how patients are selected to participate in a clinical trial or how they know where to start? Maybe your doctor has mentioned the possibility of you or a loved one being in […]
-
Thompson Cancer Survival Center has boasted a strong mission to participate in research and clinical trials since its inception. Thompson frequently participates as an approved site in national trials. Such participation ensures our patients and providers are offered access to the latest in novel therapeutics or treatments. The Thompson team also initiates trials or studies […]
-
“I consider the first annual Clinical Trials Symposium a huge success!” Susie Owenby, System Director of Research for Covenant Health System responded with excitement when asked about the recent event. She went on to explain, “It was well attended by medical providers, ancillary staff, and the community, both in-person and virtually. Getting the word out […]
-
Content authored by Jessica Severt RN, BSN, Clinical Research Nurse Coordinator at Thompson Cancer Survival Center Clinical Trials: Phases and Types Did you know that most drugs go through at least 3 different levels of clinical trial testing before they are approved? It may also surprise you to know, that even after a drug is […]
-
This content was written by Shelly Abrams, RN, BSN, Clinical Research Coordinator Can Mobile Devices Identify Post-Treatment Problems Early? ON TRAX – Evaluating a mobile technology monitoring device used in patients with inoperable Stage 3 Lung Cancer Lung cancer is one of the leading causes of cancer deaths in men and women worldwide. People […]